These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21334302)

  • 1. Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).
    Zhang W; Ahmad G; Torben W; Siddiqui AA
    Acta Trop; 2011 May; 118(2):142-51. PubMed ID: 21334302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice.
    Ahmad G; Zhang W; Torben W; Noor Z; Siddiqui AA
    Int J Infect Dis; 2010 Sep; 14(9):e781-7. PubMed ID: 20630783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse.
    Zhang W; Ahmad G; Torben W; Siddiqui AA
    Parasite Immunol; 2010 Apr; 32(4):252-8. PubMed ID: 20398225
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Zhang W; Ahmad G; Molehin AJ; Torben W; Le L; Kim E; Lazarus S; Siddiqui AJ; Carter D; Siddiqui AA
    J Investig Med; 2018 Dec; 66(8):1124-1132. PubMed ID: 29997146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic.
    Ahmad G; Zhang W; Torben W; Ahrorov A; Damian RT; Wolf RF; White GL; Carey DW; Mwinzi PN; Ganley-Leal L; Kennedy RC; Siddiqui AA
    J Infect Dis; 2011 Nov; 204(9):1437-49. PubMed ID: 21921206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine.
    Ahmad G; Zhang W; Torben W; Haskins C; Diggs S; Noor Z; Le L; Siddiqui AA
    Parasitol Res; 2009 Nov; 105(6):1767-77. PubMed ID: 19809833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni.
    Ahmad G; Torben W; Zhang W; Wyatt M; Siddiqui AA
    Parasite Immunol; 2009 Mar; 31(3):156-61. PubMed ID: 19222788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.
    Molehin AJ; Sennoune SR; Zhang W; Rojo JU; Siddiqui AJ; Herrera KA; Johnson L; Sudduth J; May J; Siddiqui AA
    Parasitol Res; 2017 Nov; 116(11):3175-3188. PubMed ID: 29026995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine.
    Zhang W; Ahmad G; Torben W; Noor Z; Le L; Damian RT; Wolf RF; White GL; Chavez-Suarez M; Podesta RB; Kennedy RC; Siddiqui AA
    J Infect Dis; 2010 Apr; 201(7):1105-12. PubMed ID: 20187746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection.
    Da'Dara AA; Skelly PJ; Walker CM; Harn DA
    Parasite Immunol; 2003; 25(8-9):429-37. PubMed ID: 14651590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.
    Ahmad G; Zhang W; Torben W; Damian RT; Wolf RF; White GL; Chavez-Suarez M; Kennedy RC; Siddiqui AA
    Vaccine; 2009 May; 27(21):2830-7. PubMed ID: 19366570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon.
    Zhang W; Ahmad G; Le L; Rojo JU; Karmakar S; Tillery KA; Torben W; Damian RT; Wolf RF; White GL; Carey DW; Carter D; Reed SG; Siddiqui AA
    Parasitol Res; 2014 Jun; 113(6):2239-50. PubMed ID: 24728521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4.
    Siddiqui AA; Phillips T; Charest H; Podesta RB; Quinlin ML; Pinkston JR; Lloyd JD; Paz M; Villalovos RM; Pompa J
    Infect Immun; 2003 Jul; 71(7):3844-51. PubMed ID: 12819068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons.
    Karmakar S; Zhang W; Ahmad G; Torben W; Alam MU; Le L; Damian RT; Wolf RF; White GL; Carey DW; Carter D; Reed SG; Siddiqui AA
    Vaccine; 2014 Mar; 32(11):1296-303. PubMed ID: 24397898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Strong Humoral Immune Response Induced by a Vaccine Formulation Containing rSm29 Adsorbed to Alum Is Associated With Protection Against
    Alves CC; Araujo N; Bernardes WPOS; Mendes MM; Oliveira SC; Fonseca CT
    Front Immunol; 2018; 9():2488. PubMed ID: 30450095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
    Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
    Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models.
    Torben W; Ahmad G; Zhang W; Siddiqui AA
    Vaccine; 2011 Mar; 29(12):2262-71. PubMed ID: 21277404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2.
    Pearson MS; Pickering DA; McSorley HJ; Bethony JM; Tribolet L; Dougall AM; Hotez PJ; Loukas A
    PLoS Negl Trop Dis; 2012; 6(3):e1564. PubMed ID: 22428079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon.
    Siddiqui AA; Pinkston JR; Quinlin ML; Saeed Q; White GL; Shearer MH; Kennedy RC
    Vaccine; 2005 Feb; 23(12):1451-6. PubMed ID: 15670880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice.
    Le L; Zhang W; Karmakar S; Ahmad G; Torben W; Siddiqui AA
    Parasitol Res; 2014 Mar; 113(3):1195-200. PubMed ID: 24452916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.